Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 190-193

  Bhatt, Rama ^a   De Vries, Peter ^a   Tulinsky, John ^a   Bellamy, Garland ^a   Baker, Brian ^a   Singer, Jack W ^a   Klein, Peter ^a  

^a Cell Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; POLYGLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED C57BL; MICE, NUDE; POLYGLUTAMIC ACID; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037413560     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020022r     Document Type: Article

References (17)

1. Muggia, F. Twenty years later: Review of clinical trials with camptothecin sodium (NSC-10080). In Camptothecins: New Anticancer Agents; Potmesil, M., Pinedo H., Eds.; CRC Press: Boca Raton, FL, 1995; pp 43-50.
2. Giovanella, B. C.; Hinz, H. R.; Kozielski, A. J.; Stehlin, J. S.; Silber, R.; Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 1991, 51, 3052-3055.
3. Burke, T. G.; Mi, Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. 1993, 36, 2580-2582.
4. Fassberg, J.; Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992, 81, 676-684.
5. Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32, 715-720.
6. Zhao, H.; Lee, C.; Sai, P.; Choe, Y. H.; Boro, M.; Pendri, A.; Guan, S.; Greenwald, R. B. 20-O-Acylcamptothecin derivatives: Evidence for lactone stabilization. J. Org. Chem. 2000, 65, 4601-4606.
7. Cao, Z.; Harris, N.; Kozielski, A.; Vardeman, D.; Stehlin, J. S.; Giovanella, B. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J. Med. Chem. 1998, 41, 31-37.
8. Conover, C. D.; Greenwald, R. B.; Pendri, A.; Shum, K. L. Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Des. 1999, 14, 499-506.
9. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Lee, C.; Choe, Y. H.; Gilbert, C.; Martinez, A.; Xia, J.; Wu, D.; Hsue, M. M. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 1998, 6, 551-562.
10. Caiolfa, V. R.; Zamai, M.; Fiorino, A.; Frigerio, E.; Pellizzoni, C.; d'Argy, R.; Ghiglieri, A.; Castelli, M. G.; Farao, M.; Pesenti, E.; Gigli, M.; Angelucci, F.; Suarato, A. Polymer-bound camptothecin: Initial biodistribution and antitumour activity studies. J. Controlled Release 2000, 65, 105-119.
11. Okuno, S.; Harada, M.; Yano, T.; Yano, S.; Kiuchi, S.; Tsuda, N.; Sakamura, Y.; Imai, J.; Kawaguchi, T.; Tsujihara, K. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000, 60, 2988-2995.
12. Li, C.; Yu, D. F.; Newman, R. A.; Cabral, F.; Stephens, L. C.; Hunter, N.; Milas, L.; Wallace, S. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid) - Paclitaxel conjugate. Cancer Res. 1998, 58, 2404-2409.
13. Li, C.; Price, J. E.; Milas, L.; Hunter, N. R.; Ke, S.; Yu, D. F.; Charnsangavej, C.; Wallace, S. Antitumor activity of poly(L-glutamic acid) - Paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 1999, 5, 891-897.
14. Singer, J. W.; de Vries, P.; Bhatt, R.; Tulinsky, J.; Klein, P.; Li, C.; Milas, L.; Lewis, R. A.; Wallace, S. Conjugation of camptothecins to poly-(L-glutamic acid). Ann. N.Y. Acad. Sci. 2000, 922, 136-150.
15. Singer, J. W.; Bhatt, R.; Tulinsky, J.; Buhler, K. R.; Heasley, E.; Klein, P.; de Vries, P. Water-Soluble Poly-(L-glutamic acid)-Gly-Camptothecin Conjugates Enhance Camptothecin Stability and Efficacy in Vivo. J. Controlled Release 2001, 74, 243-247.
16. de Vries, P.; Kumar, A.; Bellamy, G.; Nudelman, E.; Brannan, M.; Lewis, R. A.; Singer, J. W.; Baker, B. Pharmacokinetics (PK) and biodistribution of poly-(L)-glutamic acid (PG) paclitaxel (TXL) (CT-2103) in mice with subcutaneous B-16 melanomas. Presented at the Proceedings of the 11th AACR-NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, November 7-10, 2000; Poster 555.
17. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Controlled Release 2000, 65, 271-284.